Vedolizumab-4030: Understand the Outcomes of Inflammatory Bowel Disease (IBD) Patients Treated with Biologics in Taiwan – A Decentralized Vedolizumab and Biologic Agents Core Assessments in IBD CollaborationFirst published 22/08/2022 Last updated 23/04/2024 EU PAS number: EUPAS48289StudyFinalised